RSS  JOBS   SITE MAP 
 HOME 
PHARMA
BIO TECHNOLOGY
MEDICAL TECHNOLOGY
 RESOURCE CENTER 
 SUBSCRIBE 
 SUBSCRIBE ASIA DIGEST 
  Friday, September 3, 2010 SEARCH     
 
 
BIO AUSTRALIA
BIO CHINA
BIO INDIA
BIO INDONESIA
BIO JAPAN
BIO KOREA
BIO MALAYSIA
BIO NEW ZEALAND
BIO PHILIPPINES
BIO SINGAPORE
BIO TAIWAN
BIO THAILAND
 
 
Get the latest news on life sciences in your mail box
Name
E-Mail Id
 
 
Advertisement



















 
Bio Technology  News  Story
Carotech commences trail on Tocotrienols to evaluate neuroprotective effects

Singapore, Oct 5, 2009: Carotech, a subsidiary of Hovid and, one of the largest GMP-certified pharmaceutical companies in Malaysia announced the commencement of the largest human clinical trial on tocotrienols, specifically evaluating the neuroprotective and anti-atherogenic properties of Tocomin SupraBio – patented and bioenhanced natural full spectrum palm tocotrienol complex.

The release noted that it is a 3-year randomized double blind placebo controlled study involving 400 subjects and funded by the Malaysian Palm Oil Board and the Ministry of Science, Malaysia. Carotech provides all the soft gel capsules (based on Tocomin SupraBio) for this study.

This phase II clinical trial evaluates the neuroprotective properties of Tocomin SupraBio by evaluating and reviewing white matter changes in the brain using magnetic resonance imaging (MRI) before, during and after supplementation. White matter lesions represent areas of subclinical infarct and may be an independent prognostic measure of future stroke risk.

Large animal studies conducted by Prof. Chandan Sen and his group of researchers at The Ohio State University Medical Center showed extremely low level of Tocomin natural full spectrum palm tocotrienol complex prevented glutamate-induced death of neuron cells in mice through the inhibition of c-Src kinase and 12-lipoxygenase. In addition, tocotrienol-supplemented rats showed more protection against stroke-induced injury (significant reduction in volume of cerebral infarct) compared with matched controls. 

In addition to the neuroprotective effect, the study will also evaluate the effects of tocotrienols on blood parameters such as total lipid profile, Apo-B, C-reactive protein, antioxidant profile, Lp(a) and lipid peroxidation (secondary objectives).

"Tocomin SupraBio is a patented self-emulsifying tocotrienol formulation that enhances oral absorption of tocotrienols by an average of 250% and independent of food intake. We are proud to be chosen and associated with this largest ever clinical trial on tocotrienols. Being the largest and only GMP-certified tocotrienol producer, it underscores Carotech’s emphasis on science and clinical trials to bring this unique form of vitamin E to our customers," said WH Leong, the Vice President of Carotech

© BioSpectrum Bureau
  Email this articleComment on this article   Print this article
 
Advertisement





 
   
 
Google
BioSpectrumAsia.com BioSpectrumIndia.com Web

About BioSpectrum | How to Advertise | Jobs at BioSpectrum | Jobs at CyberMedia | Contact Us | Privacy Statement



CyberMedia Network Websites


[Voice&Data]  [PCQuest]  [CIOL]  [Dataquest]  [Living Digital]  [IDC India]
[DQ Channels]  [The DQweek]  [DARE]  
[CyberMedia Events] [CyberMedia Digital]  [Cyber Astro]  [CyberMedia India]  [Global Services]  [BioSpectrum]

 
Copyrights are reserved for BioSpectrum ; Designed by : Altered Black